Racial outcomes in patients with diabetic cardiomyopathy treated with an aldose reductase inhibitor: the ARISE-HF trial
Jose L. Batista, Yuxi Liu, Javed Butler, Stefano Del Prato, Justin A Ezekowitz, Carolyn S P Lam, Thomas H Marwick, Julio Rosenstock, W H Wilson Tang, Riccardo Perfetti, Alessia Urbinati, Faiez Zannad, Onyedika Ilonze, James L JanuzziBackground
Racial and ethnic differences in diabetic cardiomyopathy (DbCM) exist, with black and Hispanic participants showing poorer health status. It remains unclear whether these differences affect the natural progression of the disease. We aimed to evaluate disease progression in individuals with DbCM, as well as racial differences in the response to AT-001.
Methods
A total of 625 participants with DbCM were randomised to either placebo or AT-001 and followed for 15 months. The primary outcome was change in peak oxygen uptake (peak VO 2 ) and secondary outcomes included Kansas City Cardiomyopathy Questionnaire (KCCQ) and Physical Activity Scale for the Elderly scores. Analyses were stratified by race and ethnicity (black, Hispanic, white).
Results
Black and Hispanic participants who received placebo experienced greater declines in peak VO 2 (−0.74 and −1.67 mL/kg/min, respectively) compared with white participants (−0.23 mL/kg/min, p=0.005). AT-001 demonstrated a non-statistically significant trend towards slower declines in peak VO 2 in black and Hispanic participants (−0.31 and −0.62 mL/kg/min, p=0.29, respectively). Black participants who received placebo had the largest declines in most KCCQ scores.
Conclusion
Black and Hispanic participants with DbCM experienced faster disease progression, with black participants showing the most pronounced functional and quality of life declines. The effect of AT-001 on peak VO
2
changes was not statistically significant with similar effects between racial and ethnic groups (
Trial registration number